Several local and regional startups were showcased recently at UNLV Innovation Day, where Dr. Jeffrey Cummings, director of the Chambers-Grundy Center for Transformative Neuroscience in the Department of Brain Health at the Kirk Kerkorian School of Medicine at UNLV, was excited about the growth of the life sciences ecosystem.

While Alzheimer’s remains a complex disease, recent clinical trials and research efforts have expanded, emphasizing biomarkers and better patient targeting to improve drug development success rates.

Delayed and imprecise Alzheimer’s diagnoses in the UK are limiting patient access to clinical trials despite rapid growth in experimental treatments.

The number of national clinical trials for Alzheimer’s therapies has increased by 40 percent in the last decade. That’s according to UNLV brain health researcher Jeffrey Cummings’ 10th annual report, published Tuesday in the Alzheimer’s Association’s research journal.

Dr Jeffrey Cummings, of the University of Nevada, Las Vegas, has published an annual review of clinical trials for Alzheimer’s drugs for the past decade. The latest review, published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions, reveals a shifting approach to the disease, with fewer drugs designed to remove amyloid and more targeting tau, inflammation and other immune system pathways.

Every year, world‑leading dementia researcher Dr Jeffrey Cummings releases a global snapshot of Alzheimer’s trials – and the 2026 update has just been published. Right now, researchers are evaluating 158 medicines across 192 trials – marking an impressive 40% rise over the past decade. This year’s review also shows the most diverse Alzheimer’s drug pipeline to date.

The global effort to find a cure for Alzheimer’s disease has seen a 35% increase in the number of clinical trials and a 40% increase in therapies being tested since 2016, according to a new report from a UNLV researcher.

In 2019, researchers at UNLV, the University of San Diego and Amsterdam University reported that about 99% of Alzheimer’s clinical trials had failed. After decades of setbacks, however, newer treatments are beginning to show success in clinical trials and are now moving through regulatory review. Scientists say these incremental advances could start to shift the trajectory of the disease, even as the number of people diagnosed continues to grow.

Las Vegas medical school study shows 35% increase in clinical trials since 2016.

Axsome Therapeutics’ Auvelity expanded its label to include treating agitation in Alzheimer’s disease patients. It’s just the second FDA-approved drug for this indication, and Axsome’s pill has a safety advantage.

Four years after gaining FDA approval for Auvelity to treat major depressive disorder (MDD), Axsome Therapeutics has tacked on a second nod in the United States for the first-in-class medicine to treat agitation associated with dementia caused by Alzheimer’s disease.

The agency’s decision marks the first approval of a drug with this specific mechanism of action for one of the most burdensome and clinically challenging symptoms of the disease.